Oncocyte Corporation (OCX)
OCX moved a median of 0.00% 30 minutes after news, and -0.33% by the close. How OCX actually reacts to news — the realized, point-in-time move the market made, measured across 141 labeled events over the last three years with zero look-ahead.
OCX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 23% | 106 |
| 30-min | 0.00% | 47% | 125 |
| 60-min | 0.00% | 47% | 131 |
| to close | -0.33% | 44% | 140 |
| Middle 50% of OCX reactions | -2.86% to +2.07% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 141 |
Half of all Oncocyte Corporation news events land between -2.86% and +2.07% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How OCX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 76 | 0.00% | 41% | -0.67% |
| Rating reiterations | 26 | +0.14% | 50% | -0.49% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how OCX ranks against every other measured name →
That’s how OCX usually reacts — get an email when it moves on news →Email me when OCX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to OCX's baseline. Nothing else.
Recent OCX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors | Press release | PR Newswire | — | — | |
| Form 8-K Oncocyte Corp For: Jun 13 | SEC filing · Form 8-K | SEC EDGAR | -2.17% | +15.52% | |
| Medicare Boosts Reimbursement for Oncocyte’s Flagship Technology | Press release | GlobeNewswire | +3.03% | +6.52% | |
| Form ARS Oncocyte Corp For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +7.31% | |
| Form DEF 14A Oncocyte Corp For: May 14 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +7.31% | |
| Form DEFA14A Oncocyte Corp | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +7.31% | |
| Form 10-Q Oncocyte Corp For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.35% | -1.77% | |
| Form 8-K Oncocyte Corp For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -0.35% | -1.77% | |
| Oncocyte Reports Q1 2025 Results and Business Progress | Press release | GlobeNewswire | -0.35% | -1.77% | |
| Oncocyte to Release First Quarter 2025 Results on May 12, 2025 | Press release | GlobeNewswire | -0.36% | +1.43% | |
| Oncocyte Provides Positive Update on Clinical Trial Progress | Press release | GlobeNewswire | -0.63% | -3.75% | |
| Oncocyte’s Proprietary Assay Demonstrates Long-Term Clinical Validity | Press release | GlobeNewswire | +0.00% | -1.27% | |
| Form 8-K Oncocyte Corp For: Apr 11 | SEC filing · Form 8-K | SEC EDGAR | +1.06% | +1.77% | |
| Form EFFECT Oncocyte Corp | SEC filing · Form EFFECT | SEC EDGAR | -8.80% | -13.52% | |
| Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference | Press release | GlobeNewswire | -2.39% | +1.03% | |
| Form S-1 Oncocyte Corp | SEC filing · Form S-1 | SEC EDGAR | — | -0.97% | |
| Form 10-K Oncocyte Corp For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -6.04% | -16.48% | |
| Form 8-K Oncocyte Corp For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | -6.04% | -16.48% | |
| Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts | Press release | GlobeNewswire | -6.04% | -16.48% | |
| Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025 | Press release | GlobeNewswire | +0.00% | -1.96% | |
| Form 8-K Oncocyte Corp For: Mar 04 | SEC filing · Form 8-K | SEC EDGAR | +3.25% | -1.68% | |
| Form D Oncocyte Corp | SEC filing · Form D | SEC EDGAR | +0.00% | -0.76% | |
| Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference | Press release | GlobeNewswire | -2.29% | +8.72% | |
| Form 8-K Oncocyte Corp For: Feb 06 | SEC filing · Form 8-K | SEC EDGAR | -1.48% | +1.97% | |
| Oncocyte Prices $29.1 Million Equity Offering | Press release | GlobeNewswire | -1.48% | +1.97% | |
| Form 8-K Oncocyte Corp For: Jan 02 | SEC filing · Form 8-K | SEC EDGAR | — | -0.45% | |
| Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer | Press release | GlobeNewswire | +0.00% | -3.04% | |
| Oncocyte Expands Market Opportunity for VitaGraft™ Kidney | Press release | GlobeNewswire | +0.00% | -4.31% | |
| Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings | Press release | GlobeNewswire | +0.00% | -0.40% | |
| Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study | Press release | GlobeNewswire | -2.09% | -3.77% | |
| Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms | Press release | GlobeNewswire | -0.87% | -3.02% | |
| Form 10-Q Oncocyte Corp For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.67% | -2.00% | |
| Form 8-K Oncocyte Corp For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -1.67% | -2.00% | |
| Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025 | Press release | GlobeNewswire | -1.67% | -2.00% | |
| Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12 | Press release | GlobeNewswire | — | +0.00% | |
| Form EFFECT Oncocyte Corp | SEC filing · Form EFFECT | SEC EDGAR | — | +0.65% | |
| Form S-3/A Oncocyte Corp | SEC filing · Form S-3 | SEC EDGAR | -1.73% | -2.50% | |
| Form S-3 Oncocyte Corp | SEC filing · Form S-3 | SEC EDGAR | +2.31% | +2.97% | |
| Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles | Press release | GlobeNewswire | +2.31% | +2.97% | |
| Form 8-K Oncocyte Corp For: Oct 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -4.60% | |
| Form D Oncocyte Corp | SEC filing · Form D | SEC EDGAR | -2.89% | -1.29% | |
| Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form 8-K Oncocyte Corp For: Oct 02 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -6.29% | |
| Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules | Press release | GlobeNewswire | +0.00% | -6.29% | |
| Oncocyte Signs Leading Transplant Centers in US and Germany | Press release | GlobeNewswire | +0.00% | -6.29% | |
| Form DEF 14A Oncocyte Corp For: Sep 25 | SEC filing · Form DEF | SEC EDGAR | — | +2.41% | |
| PRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics Technology | Press release | GlobeNewswire | +0.00% | -0.32% | |
| Sidoti Events, LLC's Virtual August Micro-Cap Conference | Press release | Accesswire | — | +2.01% | |
| Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study | Press release | GlobeNewswire | — | +2.01% | |
| Form 8-K Oncocyte Corp For: Aug 09 | SEC filing · Form 8-K | SEC EDGAR | — | +4.35% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the OCX section they belong to.
Where else OCX is measured.
OCX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| G1 Therapeutics, Inc. (GTHX) | 142 | +0.21% | 66% |
| InflaRx N.V. (IFRX) | 142 | 0.00% | 48% |
| ImmunoGen, Inc. (IMGN) | 140 | +0.07% | 56% |
| MEDIFIRST SOLUTIONS (MFST) | 140 | 0.00% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Oncocyte Corporation's median reaction calculated?
Every labeled OCX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 141 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of OCX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does OCX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.